Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Pembrolizumab 25 MG/ML [Keytruda]
United Therapeutics Europe Ltd
Lung Cancer, Nonsmall Cell
1 trial -
Pemetrexed
Regeneron UK Limited
Carcinoma,Non-Small-Cell Lung
1 trial -
Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, TAGRISSO 40 mg film-coated tablets, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 100 mg powder for concentrate for solution for infusion, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
Pemigatinib
Incyte
Unresectable Cholangiocarcinoma
1 trial -
Pentoxifylline
United Therapeutics Europe Ltd
Kidney Failure, Chronic
1 trial -
Pergolide
BRIGHT MINDS BIOSCIENCES INC.
Cocaine-Related Disorders
1 trial -
Phase 1: Olanzapine
Shanghai Mental Health Center
Schizophrenia
1 trial -
Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide with a Non-Randomized, Single Arm US Extension of Mosunetuzumab in Combination with Lenalidomide in Patients with Follicular Lymphoma After at Least One Line of Systemic Therapy
Hoffmann-La Roche
Relapsed/refractory follicular lymphoma
1 trial -
Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Phesgo 600 mg/600 mg solution for injection, Herceptin 150 mg powder for concentrate for solution for infusion
Hoffmann-La Roche
HER2-POSITIVE EARLY BREAST CANCER
1 trial -
Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Phesgo 600 mg/600 mg solution for injection
Fondazione Telethon ETS
Invasive Breast Cancer
1 trial -
Phesgo 600 mg/600 mg solution for injection, Herceptin 600 mg solution for injection in vial, Perjeta 420 mg concentrate for solution for infusion, Phesgo 1200 mg/600 mg solution for injection, Kadcyla 160 mg powder for concentrate for solution for infusion.
Hoffmann-La Roche
Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer
1 trial -
Physiotherapy
United Therapeutics Europe Ltd
Sciatica
1 trial -
Picosulfate sodium, magnesium oxide, citric acid
Universal Integrated
Bowel Preparation Before Colonoscopy
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Irritability Associated With Autism Spectrum Disorder
2 trials -
Pimavanserin
Acadia Pharmaceuticals B.V.
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
2 trials -
Pimavanserin tartrate (ACP-103)
Acadia Pharmaceuticals B.V.
Parkinson's Disease Psychosis
4 trials -
Pimodivir 600 mg
Janssen Cilag International NV
Influenza A
1 trial -
Pioglitazone
Takeda
HIV-Associated Lipodystrophy Syndrome
1 trial -
Pioglitazone and Azilsartan
Takeda
Type 2 Diabetes
1 trial -
Pioglitazone and Glimepiride
Takeda
Diabetes Mellitus
1 trial -
Pioglitazone, EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE, GLIMEPIRIDE, GLICLAZIDE, METFORMIN HYDROCHLORIDE, GLIPIZIDE, METFORMIN HYDROCHLORIDE, EMPAGLIFLOZIN, GLIQUIDONE, Placebo for Actos 15 mg tablets, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
Celltrion Healthcare Australia Pty Ltd
Type 2 diabetes mellitus (T2DM)
1 trial -
Pioglitazone-Azilsartan
Takeda
Diabetes Mellitus, Type 2
1 trial -
Placebo
Jazz Pharmaceuticals Ireland Limited
Multiple Sclerosis
1 trial -
Placebo
United Therapeutics Europe Ltd
Idiopathic Pulmonary Fibrosis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources